NASDAQ:SCLX
READ THE FULL SCLX RESEARCH REPORT
Scilex Holding Company (NASDAQ:SCLX) is a revenue-generating company that is focused on addressing one of the biggest issues facing humanity today—that of the overuse of opioids. Scilex is focused on developing non-opioid pain management products that provide the relief patients so desperately need, while avoiding the debilitating addiction that often comes with the use of opioids. Roughly 112,000 Americans died in 2023 from overdoses and there we have no doubt that a good number of those involved opioid use at some point to reduce physical pain of various types.
Scilex continues to grow its product offerings and distribution channels, leading to more patients being helped and more revenue coming in. Just in the last month the company has announced:
• One of its primary drugs, Ztlido, according to the company, recently reached the one million mark in terms of patients treated.
o Additionally, the company noted that, based on prescription data from Symphony Health, Ztlido is now the number one prescribed non-opioid branded pain medication by pain specialists in the U.S.
o Management also noted that 89% of patients using Ztlido expressed satisfaction with the drug.
• Another drug we have written extensively about, Gloperba, is expected to be launched in the first half of 2024.
o As a reminder, Gloperba is the first and only liquid oral version of the anti-gout medicine colchicine.
▪ Gout impacts approximately 9.2 million people in the U.S.
• Finally, the company announced a funding raise by issuing 5,882,353 shares of common stock and an equal number of warrants to raise approximately $9.2 million before expenses.
o We applaud this move and believe the additional liquidity will prove crucial to the expansion of the company’s product line and distribution channels.
These announcements reinforce our belief that SCLX is poised to resume its move higher and that investors continue to underestimate the value of treatments the company currently has and is developing. We urge investors to take a look at a company that is earning revenue, growing that revenue in a meaningful way, and adding to its portfolio of very important treatments before the rest of the investing community realizes the story developing at Scilex.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
